

Association of Two Angiogenic Genes Polymorphism with Clinical Course and Prognosis of Non-Hodgkin Lymphoma in Egyptian Patients

Dina EL DAHSHAN¹, Shaymaa SHOLKAMY¹, Enass AZZAB¹,
Mohamed EL WAKIL², Amr EL SAYED³

¹ Beni-Suef University Faculty of Medicine, Department of Clinical Pathology

² Beni-Suef University Faculty of Medicine, Department of Oncology

³ Beni-Suef University Faculty of Post Graduate Studies for Advanced Science,
Department of Biotechnology, Beni-Suef, EGYPT

ABSTRACT

Angiogenesis is a main process that helps in the growth and survival of many haematopoietic neoplasms one of them is non-Hodgkin's lymphomas (NHLs). Both the vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), are key initiators of angiogenesis, they can act by direct stimulation of tumour cells or by influencing the surrounding microenvironment. Previous studies suggested that their expression affected the course and progression of the disease. The current study aimed to reveal the relationship between the genotyping of VEGF and bFGF genes and the susceptibility to NHL and its' association with disease course and prognosis. PCR-RFLP technique was used for detection of VEGF (rs3025039), and bFGF (rs308395) mutations in 40 NHL patients and 40 healthy individuals as a control group. Patients carrying the mutant T allele of VEGF gene were more than twice more susceptible to NHL (OR= 2.714, p=0.039), and its presence was also significantly higher in patients with B symptoms (p< 0.001). Moreover, the polymorphic VEGF was significantly higher among patients who did not respond to treatment (42.1%) (p= 0.017). The presence of the polymorphic bFGF mutant G showed significantly higher susceptibility to aggressive histological subtypes of NHL compared to those with indolent subtypes (p= 0.010, OR 17.818), and compared to normal controls (p= 0.014, OR 3.818). These findings imply that polymorphism of angiogenic factors such as VEGF and bFGF are related to clinical characteristics and histological subtype of NHL, which showed prognostic significance that might serve as future markers for tailoring treatment and monitoring response in these patients.

Keywords; NHL, Angiogenesis, VEGF, bFGF, Gene polymorphism

INTRODUCTION

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative malignancies having various behaviors, clinical presentations, disease course and prognosis. Many biological and clinical factors affect the clinical course and the treatment decisions. Biological mechanisms influencing to the course of NHL are still not fully understood.¹

The growth and progression of lymphoma might be augmented by angiogenesis. Both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are key players in this process. The VEGF is a powerful mediator of angiogenesis both by autocrine stimulation of tumour cells in addition to its paracrine influence on proangiogenic tumour microenvironment.¹

Some studies reported that the VEGF expression reflected the proliferative activity in lymphomas. Because of the heterogeneity of the disease, its variable classifications and different methods of analysis; it is controversial if the enhancement of microvessel density and the proangiogenic factors can be of predictive value for prognosis in NHL.²

The human VEGF gene is located on chromosome 6p21.3 it is formed of 8 exons separated by 7 introns.³ Studies have described many different single nucleotide polymorphisms (SNPs) in the VEGF gene.^{4,5} While the human bFGF gene is located on chromosome 4.⁶ Polymorphisms in the promoter region of the bFGF gene can interfere with the binding sites of transcription factor or may produce new binding sites and, therefore, influence bFGF biological activity.⁷

In the current study, we analysed the C to T substitution at position 936 in the 3'-untranslated region of the VEGF gene, together with the C to G substitution at position -921 in the promoter region of the bFGF gene, in an attempt to reveal if their substitution is associated with susceptibility to NHL or aggressiveness of the disease in Egyptian patients.

PATIENTS and METHODS

Patients and Controls:

The present study was conducted on 40 NHL patients (23 males and 17 females; aged 24-75 years, mean age 47.5 years). Patients were recruited from the Department of Oncology, Beni-Suef university hospital. Forty age and sex matched healthy individuals of both sexes served as controls. Informed consents were obtained from patients and controls in advance. The study was approved by the Research Ethical Committee of Faculty of Medicine, Beni-Suef University and was conducted in accordance with the Helsinki Declaration of Human Rights. The patients' characteristics and clinical data are shown in Table 1.

VEGF and bFGF Genotyping: From each patient and control, 3-5ml of venous blood was collected on EDTA and stored at -20° C until DNA extraction was done. The VEGF and bFGF alleles were detected using a polymerase chain reaction restriction fragment length polymorphism (PCR-

Table 1. Clinical and laboratory data of NHL patients

Characteristics	NHL patients (n= 40) n (%)
Sex	
Female	17 (42.5)
Male	23 (57.5)
Age	
<60	33 (82.5)
>60	7 (17.5)
Ann Arbor stage	
I/II	23 (57.5)
III/IV	17 (42.5)
B symptoms	
Absent	14 (35)
Present	26 (65)
Number of extranodal sites	
<2	19 (47.5)
>2	21 (52.5)
Serum LDH	
Normal	27 (67.5)
Elevated	13 (32.5)
Serum B2 microglobulin	
Normal	28 (70)
Increased	12 (30)
Performance status (ECOG)	
<2	21 (52.5)
≥2	19 (37.5)
IPI risk group	
Low/low-intermediate ^{1,2}	28 (70)
Intermediate-high/high ^{3,4}	12 (30)
Survival	
Dead	3 (7.5)
Alive	37 (92.5)
Response to treatment	
Complete remission	14 (35)
Partial remission	16 (40)
No response	10 (25)

RFLP). Amplification of both the VEGF gene; (rs3025039), and the bFGF gene promoter region; (rs308395) was done in the chosen PCR conditions.⁸ Then the PCR products were digested by the restriction endonucleases; N1aIII and BseNI specific for the VEGF and bFGF polymorphisms, respectively. The products were then analysed by electrophoresis on 2% agarose gel. For the VEGF genotyping, patients lacking the N1aIII site were considered homozygous for the C allele, moreover for the bFGF genotyping, patients lacking the BseNI site were considered homozygous for the bFGF C allele. Patients' genotype was detected according to their pattern of electrophoresis. Three

electrophoretic patterns were encountered for each gene 1-VEGF: wild type CC, heterozygous CT and homozygous mutant TT, 2-bFGF: wild type CC, heterozygous CG and homozygous mutant GG.^{7,8}

Statistical Analysis

Data were coded and entered using the statistical package SPSS version 24. Data was summarized using mean and standard deviation for quantitative variables and frequencies (number of cases) and relative frequencies (percentages) for categorical variables. Comparisons between quantitative variables were done using unpaired T test.⁹ For comparing categorical data, Chi square (χ^2) test was performed. Exact test was used instead when the expected frequency is less than 5.¹⁰ Genotype and allele frequencies were calculated in the disease and the control groups. Odds ratio (OR) with 95% confidence intervals was calculated using logistic regression.¹¹ P-values less than 0.05 were considered as statistically significant.

RESULTS

The mean age in our cases was 47.50 ± 11.80 years, while control group had a mean age of 38.47 ± 10.31 years. Different patient clinical and laboratory characteristics are listed in Table 1.

Genotyping:

The VEGF wild type (CC), heterozygous (CT) and homozygous (TT) were detected in 52.5%, 42.5% and 5% of NHL patients, respectively. The bFGF wild type (CC), heterozygous (CG) and homozygous (GG) were detected in 62.5%, 32.5% and 5% respectively. The frequencies of different genotypes in both genes among cases and controls are shown in Table 2.

VEGF gene:

Comparing the different genotypes, in both the group of patients and healthy subjects, showed that the VEGF gene polymorphism was associated with NHL susceptibility, as the mutant VEGF was significantly higher among NHL patients with more than double susceptibility to the disease than individuals not carrying the polymorphism (OR= 2.714, $p= 0.039$).

Table 2. Distribution of the VEGF and bFGF genotypes in patients with NHL patients and controls

Gene	Genotype	NHL patients (40) n (%)	Control (40) n (%)
VEGF	CC	21 (52.5)	30 (75)
	CT	17 (42.5)	9 (22.5)
	TT	2 (5)	1 (2.5)
bFGF	CC	25 (62.5)	30 (75)
	CG	13 (37.5)	8 (20)
	GG	2 (5)	2 (5)

The VEGF heterozygous genotype CT showed significant susceptibility to NHL (OR= 2.698, $p= 0.047$), while the homozygous genotype didn't express statistical difference (OR=2.857, $p= 0.404$). The mutant T allele showed a higher frequency in patients (26.2%) than controls (13.8%) but it wasn't statistically significant (OR= 2.233, $p= 0.051$) Table 3.

In 26 patients who suffered from B symptoms 18 (94.7%) had statistically higher carriers of VEGF polymorphic T allele versus 8 (38.1%) who didn't ($p < 0.001$).

bFGF gene:

Mutant bFGF genotypes frequency whether heterozygous or homozygous didn't show statistical difference when comparing patients and controls ($p= 0.203$, $p= 0.860$).

Moreover it is worth noting that, the frequency of the polymorphic alleles of the bFGF (G) was higher in NHL patients (21.2%) versus 15% in control group, but this difference didn't reach statistical significance (OR= 1.529, $p= 0.307$) Table 3.

Analysis of combined genotype presentation, significant susceptibility to NHL was detected among patients carrying the heterozygous genotype of both genes (CT+CG), (OR= 6.00, $p= 0.039$) Table 4. On the other hand there was no significant difference between patients with wild and mutant genotype of bFGF regarding the presence of B symptoms ($p= 0.123$).

Patients carrying mutant forms of bFGF had significantly higher susceptibility to aggressive NHL compared to those with indolent disease ($p= 0.010$,

Table 3. Comparison of VEGF and bFGF genotypes and allelic distribution in NHL patients and controls

		Patients		Controls		p	OR	95% CI	
		Count	%	Count	%			Lower	Upper
VEGF	CC	21	52.5%	30	75.0%	Reference			
	CT	17	42.5%	9	22.5%	0.047	2.698	1.011	7.202
	TT	2	5%	1	2.5%	0.404	2.857	0.243	33.589
	CT+TT	19	47.5%	10	25%	0.039	2.17	1.053	6.999
	Allele C	59	73.8	69	86.2%	Reference			
	Allele T	21	26.2	11	13.8%	0.051	2.233	0.995	5.009
bFGF	CC	25	62.5%	30	75.0%	Reference			
	CT	13	32.5%	8	20.0%	0.203	1.950	0.697	5.543
	GG	2	5.0%	2	5.0%	0.860	1.200	0.158	9.142
	CG+GG	15	37.5%	10	25.0%	0.230	1.800	0.689	4.702
	Allele C	63	78.8%	68	85.0%	Reference			
	Allele G	17	21.2%	12	15.0%	0.307	1.529	0.677	3.453

OR 17.818), and the same relationship was detected on comparing to normal controls (p= 0.014, OR 3.818) Table 5.

Patients characterized by IPI 3 and/or 4 were more frequently carrying the VEGF polymorphism (100%) compared with patients with IPI 1 and /or 2 (25%). Moreover, the polymorphic bFGF was more frequent among patients with IPI 3 and/or 4 (33.3%) than controls (25%), but neither of these differences reached statistical significance (p= 0.998 and 0.722 respectively) Table 6.

The distribution of the VEGF alleles among patients who didn't respond to treatment was significantly higher (42.1%) than patients in complete or partial remission when compared to responders who showed (0%) VEGF mutation (p= 0.017). ver-

sus responders. But there was no significant difference between wild and mutant bFGF regarding the response to treatment (p= 0.604). Analysis of the distribution of VEGF and bFGF genotypes with respect to the age and stage was done and didn't show statistical significance.

DISCUSSION

Non Hodgkin Lymphomas are a heterogenous group of lymphoproliferative neoplasms with different presenting features, clinical course and response to treatment. In Egypt the National cancer Institute reported that NHLs are the third most common cancer in Egyptian men and the second in women.¹²

Table 4. Comparison of VEGF and bFGF combined genotypes and allelic distribution in NHL patients and controls

		Patients		Controls		p	OR	95% CI	
		Count	%	Count	%			Lower	Upper
VEGF=CC and bFGF=CC		14	35.0%	24	60.0%	Reference			
VEGF=CC and bFGF=CG		6	15.0%	6	15.0%	0.420	1.714	0.463	6.351
VEGF=CC and bFGF=GG		1	2.5%	0	0.0%	1.000	----	----	----
VEGF=CT and bFGF=CC		9	22.5%	6	15.0%	0.131	2.571	0.755	8.757
VEGF=CT and bFGF=CG		7	17.5%	2	5.0%	0.039	6.000	1.092	32.979
VEGF=CT and bFGF=GG		1	2.5%	1	2.5%	0.711	1.714	0.099	29.610
VEGF=TT and bFGF=CC		2	5.0%	0	0.0%	0.999	----	----	----

Table 5. Comparing genotypes in patients with aggressive versus patients with indolent disease

		Patients		Controls		p	OR	95% CI	
		Count	%	Count	%			Lower	Upper
VEGF	CC	13	52.0%	8	53.3%	Reference			
	CT	11	44.0%	6	40.0%	0.859	1.128	0.299	4.260
	TT	1	4.0%	1	6.7%	0.744	0.615	0.034	11.278
	CT+TT	12	48.0%	7	46.7%	0.935	1.055	0.293	3.803
bFGF	CC	11	44.0%	14	93.3%	Reference			
	CG	13	52.0%	0	0.0%	0.998	----	----	----
	GG	1	4.0%	1	6.7%	0.870	1.273	.071	22.720
	CG+GG	14	56.0%	1	6.7%	0.010	17.818	2.020	157.158

The etiology of NHLs has not been fully elucidated however, there is evolving evidence suggesting that formation of new blood vessels contributes to the progression of haematological malignancies.^{13,14} An important proangiogenic agent is VEGF, acting as a potent mediator of angiogenesis influencing proliferation, survival and tumour vascularisation. Another agent is the bFGF which plays an important role in vascular response by increasing endothelial cell proliferation, stimulating migration, and promoting angiogenesis.⁸ This explains why the analysis of VEGF and bFGF genes in haematological malignancies has been recently attracting researchers' attention.^{3,8,15}

In our study the distribution of The VEGF and bFGF genotypes and alleles were analyzed in NHL patients and controls; The VEGF genotypes CC, CT and TT were detected in 52.5%, 42.5% and

5% of NHL patients respectively. The bFGF CC, CG and GG were detected in 62.5%, 32.5% and 5% respectively. In a study done by Wrobel and colleagues⁸ on 78 NHL patients and 122 healthy controls, the reported genotype distribution was in agreement with our results; except that none of their patients presented with homozygous mutated genotype of VEGF or bFGF while it was least presented among our patients (5%). Also the allelic frequencies in our control group were in accordance with other studies as Galimberti et al.¹⁶, Kariz et al.¹⁷ and Petrovic et al.¹⁸

In the current study, individuals carrying the VEGF gene polymorphism were over two times more likely to develop NHL (OR= 2.714, p= 0.039). This relation wasn't recorded by Wrobel et al. [8] who found no significant association between VEGF gene polymorphism and susceptibility to NHL. On

Table 6. Comparing genotypes in patients with intermediate high/high IPI^{3,4} versus low/low-intermediate IPI^{1,2}

		Intermediate high/high (3,4)		Low/low Intirmediat (1,2)		p	OR	95% CI	
		n= 12	%	n= 28	%			Lower	Upper
VEGF	CC	0	0.0%	21	75.0%	Reference			
	CT	12	100.0%	5	17.9%	0.998	----	----	----
	TT	0	0.0%	2	7.1%	1.000	----	----	----
	CT+TT	12	100.0%	7	25.0%	0.998	----	----	----
bFGF	CC	8	66.7%	17	60.7%	Reference			
	CG	3	25.0%	10	35.7%	0.567	0.638	0.137	2.973
	GG	1	8.3%	1	3.6%	0.610	2.125	0.117	38.481
	CG+GG	4	33.3%	11	39.3%	0.722	0.773	0.187	3.196

the other hand the presence of VEGF T allele was higher among patients than controls in both Wrobel and colleagues⁸ patients and our patients but it didn't reach statistical significance ($p=0.051$).

The results of the present study observed that patients with VEGF polymorphic features were more frequently presented with a higher IPI score when compared to both patients with low or intermediate IPI score and controls. This relationship didn't show statistical significance ($p=0.998$). The same tendency of individuals carrying the VEGF T variant were over three times more likely to develop NHL was reported by Wrobel et al.⁸

Few studies reported the role of polymorphic features in the genes coding for these two proangiogenic agents. A Chinese study on VEGF polymorphism analysed DNA samples of 431 NHL patients using Restriction fragment length polymorphism¹⁹, reported that none of the studied genotypes were significantly associated with gender, age, tumour size, B symptoms or immunohistological subtype. In contrast, our study revealed a significantly higher ($p=0.001$) presence of B symptoms in patients carrying mutant VEGF.

Most of the studies published to date have detected the relationship of polymorphisms in the promoter region of the bFGF gene with proliferative diabetic retinopathy¹⁸ and myocardial infarction¹⁷ in patients with type 2 diabetes.

Wrobel et al.⁸, was the first study to describe the association of bFGF polymorphism and NHL. They detected a previously unreported association between bFGF gene polymorphism and a more unfavourable course of the disease. This strong tendency to aggressive NHL was detected in our work in patients carrying mutant forms of bFGF who showed more susceptibility to aggressive NHL compared to those with indolent disease ($p=0.010$, $OR=17.818$). These results were supported by Wrobel et al.⁸, who reported that aggressive NHL patients were more than twice as frequently presented with the bFGF G variant as those with the indolent histological type.

Other studies detected SNP (single nucleotide polymorphism) mediated missense mutations at various positions of FGFR that significantly con-

tributed to alterations in FGFR activity with a corresponding increase in tumorigenesis.²⁰ In their investigation of the FGFR genotype in more than 400 NHL patients, both Cha et al.²¹, and Gao et al.²², they reported significantly higher mutant genotype among NHL patients than controls.

In the present study the analysis of mutant bFGF genotypes revealed higher frequency among patients than controls but did not show a statistical difference ($p=0.230$). These results are in agreement with Cha et al.²¹, and Gao et al.²² Moreover it is worth noting that, the frequency of the polymorphic G alleles of bFGF was higher in NHL patients (21.2%) compared to 15% in control group, but this difference did not reach a statistical significance ($OR=1.529$, $p=0.307$).

The present study showed significantly higher polymorphic forms of VEGF alleles among non responders to treatment than those in remission ($p=0.017$). This relation was not reported in previous studies Diao et al.¹⁹, who did not report an association of VEGF genotype and response to treatment. They also stated it was not significantly associated with gender, age, tumour size or immunohistological type. These findings were in agreement with our results except for the histological subtypes, where patients with mutant G allele of bFGF had significantly higher susceptibility to aggressive NHL compared to those with indolent disease and normal controls respectively ($p=0.010$, $OR=17.818$), ($p=0.014$, $OR=3.818$).

Enhanced angiogenesis may explain our findings of VEGF and bFGF mutant association with NHL especially the aggressive subtypes. Many studies correlated the serum levels and genotype of VEGF and bFGF and the and their NHL disease course and its prognosis.

This study could not detect the association between serum levels of VEGF and bFGF and the course of the disease due to limitation of sample size. This limitation could be a drawback in the study, but it will be taken as a future step to a broader study including larger number of both patients and healthy controls.

Acknowledgment:

The authors would like to express their deepest gratitude for Professor Seham Omar, Professor of Clinical Pathology, Faculty of Medicine, Beni-Suef University for her consistent help and support throughout the work.

REFERENCES

1. Ribatti D, Vacca A, Nico B, et al. Angiogenesis spectrum in the stroma of Bcell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. *Eur J Haematol* 56: 45-53, 1996.
2. Hazar B, Paydas S, Zortudemir S, et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. *Leuk Lymphoma* 44: 2089-2093, 2003.
3. Vincenti V, Cassano C, Rocchi M, Persico M. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. *Circulation* 93: 1493-1495, 1996.
4. Brogan I, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. *Hum Immunol* 60: 1245-1249, 1999.
5. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. *Diabetes* 51: 1635-1639, 2002.
6. Lafage-Pochitaloff M, Galland F, Simonetti J, et al. The human basic fibroblast growth factor gene is located on the long arm of chromosome 4 at bands q26-q27. *Oncogene Res* 5: 241-244, 1990.
7. Beránek M, Tschöplová S, Kanková K, et al. Genetic variation in the promoter region of the basic fibroblast growth factor gene. *Hum Immunol* 64: 374-377, 2003.
8. Wrobel T, Mazur G, Dziętczenia J, et al. VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma. *Biomed Res Int* 2013: 159813, 2013.
9. Chan YH. *Biostatistics 102: Quantitative Data-Parametric & Non-parametric Tests*. Singapore Med J 44: 391-396, 2003.
10. Chan YH. *Biostatistics 103: Qualitative Data -Tests of Independence*. Singapore Med J 44: 498-503, 2003.
11. Chan YH. *Biostatistics 202: logistic regression analysis*. Singapore Med J 45: 149-153, 2004.
12. El-Sayed L, Ghoneim H, Abdel Rahman M, et al. Prognostic value of FOXP3 and TGF- β expression in both peripheral blood and lymph nodes in patients with B-non Hodgkin's lymphoma. *Alex J Med* 7: 253-265, 2013.
13. Paydas S, Seydaoglu G, Ergin M, et al. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. *Leuk Lymphoma* 50: 366-373, 2009.
14. Klein S, Roghani M, Rifkin DB. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. *EXS* 79: 159-192, 1997.
15. Jorgensen JM, Sorensen FB, Bendix K, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. *Leuk Lymphoma* 50:1647-1660, 2009.
16. Galimberti S, Nagy B, Palumbo GA, et al. Vascular endothelial growth factor polymorphisms in mantle cell lymphoma. *Acta Haematol* 123: 91-95, 2010.
17. Karž S, Grabar D, Krkovič M, et al. Polymorphisms in the promoter region of the basic fibroblast growth factor gene are not associated with myocardial infarction in a slovene population with type 2 diabetes. *J Int Med Res* 37: 1596-1603, 2009.
18. Petrovič MG, Krkovič M, Osredkar J, et al. Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes. *Clin Exper Ophthalmol* 36: 168-172, 2008.
19. Diao LP, Yu XM, Gao YH, et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma. *J Cancer Res Clin Oncol* 135: 1473-1481, 2009.
20. Feng S, Zhou L, Nice E C, Huang C. Fibroblast growth factor receptors: multifactorial-contributors to tumour initiation and progression. *Histol Histopathol* 30: 13-31, 2015.
21. Cha Z, Zang Y, Guo H, et al. Fibroblast growth factor receptor 4 polymorphisms and the prognosis of NHL. *Mol Biol Rep* 41: 1165-1170, 2014.
22. Gao L, Feng Z, Li Q, et al. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non hodgkin's lymphoma. *Tumour Biol* 35: 2997-3002, 2014.

Correspondence:

Dr. Dina El DAHSHAN
Beni-Suef University, Faculty of Medicine
Department of Clinical Pathology
BENI-SUEF / EGYPT

Tel: +201001002425

e-mail: dina.eldahshan@med.bsu.edu.eg

dina.eldahshan@gmail.com